SCHEMBL7923376

SCHEMBL7923376

ClN1C2CCC1CC2

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15583903 0.84 MAPK1 (0.32)
SCHEMBL12565549 0.60 PHGDH (0.32)
SCHEMBL8995158 0.55
SCHEMBL13621433 0.55
SCHEMBL3532276 0.55
SCHEMBL16869294 0.55
SCHEMBL3118431 0.52
SCHEMBL29495 0.46
SCHEMBL9720381 0.43
SCHEMBL1038693 0.43

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150361060-A1 CENTRALLY ACTIVE AND ORALLY BIOAVAILABLE ANTIDOTES FOR ORGANOPHOSPHATE EXPOSURE AND METHODS FOR MAKING AND USING THEM THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2015-12-17 US disclosed
US-8999976-B2 Modulators of cystic fibrosis transmembrane conductance regulator VERTEX PHARMACEUTICALS INCORPORATED (US) 2015-04-07 US disclosed
WO-2014127315-A1 CENTRALLY ACTIVE AND ORALLY BIOAVAILABLE ANTIDOTES FOR ORGANOPHOSPHATE EXPOSURE AND METHODS FOR MAKING AND USING THEM THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-08-21 WO disclosed
EP-2349263-B1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMA (US) 2014-04-23 EP disclosed
US-20130184313-A1 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS AND THE USES THEREOF THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2013-07-18 US disclosed
US-8461352-B2 Process for preparing azabicyclic compounds VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-06-11 US disclosed
US-8445684-B2 Nicotinic acetylcholine receptor ligands and the uses thereof PsycoGenics Inc. (US) 2013-05-21 US disclosed
US-8404865-B2 Process for preparing azabicyclic compounds VERTEX PHARMACEUTICALS (US) 2013-03-26 US disclosed
US-8389727-B2 Solid forms of N-(4-(7-Azabicyclo[2.2.1]Heptan-7-yl)-2-Trifluoromethyl)Phenyl)-4-Oxo-5-(Trifluoromethyl)-1,4-Dihydroquinoline-3-Carboxamide VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-03-05 US disclosed
US-8344147-B2 Process for preparing modulators of cystic fibrosis transmembrane conductance regulator VERTEX PHARMACEUTICAL INCORPORATED (US) 2013-01-01 US disclosed
US-20120259129-A1 Process for Preparing Azabicyclic Compounds VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-10-11 US disclosed
US-20120208841-A1 Modulators of Cystic Fibrosis Transmembrane Conductance Regulator VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-08-16 US disclosed
US-20110124869-A1 Process for Preparing Modulators of Cystic Fibrosis Transmembrane Conductance Regulator VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-05-26 US disclosed
US-20110123449-A1 Solid Forms of N-(4-(7-Azabicyclo[2.2.1]Heptan-7-yl)-2-Trifluoromethyl)Phenyl)-4-Oxo-5-(Trifluoromethyl)-1,4-Dihydroquinoline-3-Carboxamide VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-05-26 US disclosed
US-20110065928-A1 Process for Preparing Azabicyclic Compounds VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-03-17 US disclosed
US-20100152450-A1 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS AND THE USES THEREOF PSYCHOGENICS, INC. (US) 2010-06-17 US disclosed
WO-2010045212-A2 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS AND THE USES THEREOF PSYCHOGENICS, INCSTATUTS (US) 2010-04-22 WO disclosed